PEDEVCO - PED Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PEDEVCO in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PED shares.
View PED analyst ratings or view top-rated stocks.

1 brokers have issued 12-month target prices for PEDEVCO's shares. Their PED share price forecasts range from $1.95 to $1.95. On average, they expect the company's stock price to reach $1.95 in the next twelve months. This suggests a possible upside of 57.3% from the stock's current price.
View analysts price targets for PED or view top-rated stocks among Wall Street analysts.

PEDEVCO's stock was trading at $1.16 at the beginning of 2022. Since then, PED shares have increased by 6.9% and is now trading at $1.24.
View the best growth stocks for 2022 here.

PEDEVCO saw a increase in short interest in July. As of July 15th, there was short interest totaling 368,500 shares, an increase of 25.6% from the June 30th total of 293,500 shares. Based on an average trading volume of 829,300 shares, the short-interest ratio is currently 0.4 days. Approximately 1.4% of the shares of the stock are sold short.
View PEDEVCO's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our PED earnings forecast.

PEDEVCO Corp. (NYSEAMERICAN:PED) announced its earnings results on Monday, May, 16th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.02. The firm had revenue of $7.09 million for the quarter, compared to analysts' expectations of $6.63 million. PEDEVCO had a negative trailing twelve-month return on equity of 4.68% and a negative net margin of 172.08%.

Based on aggregate information from My MarketBeat watchlists, some companies that other PEDEVCO investors own include Celsion (CLSN), CEL-SCI (CVM), Energy Transfer (ET), TransEnterix (TRXC), Zosano Pharma (ZSAN), AbbVie (ABBV), Ampio Pharmaceuticals (AMPE), AutoWeb (AUTO), Biopharmx (BPMX) and Ekso Bionics (EKSO).

PEDEVCO trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PED."

PEDEVCO's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.58%) and Northern Trust Corp (0.05%). Insiders that own company stock include Harold Douglas Evans, Ivar Siem, John Douglas Schick, John J Scelfo, Moore Clark, Paul Anthony Pinkston, Simon G Kukes and Viktor Tkachev.
View institutional ownership trends.

Shares of PED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PED stock can currently be purchased for approximately $1.24.

PEDEVCO (NYSEAMERICAN:PED) has a market capitalization of $106.08 million and generates $8.06 million in revenue each year. The company earns $-32,690,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis.

PEDEVCO's mailing address is 4125 Blackhawk Plaza Cir Ste 201, DANVILLE, CA 94506-4678, United States. The official website for the company is www.pacificenergydevelopment.com. The company can be reached via phone at (713) 221-1768, via email at pr@pacificenergydevelopment.com, or via fax at 925-403-0703.